Previous 10 | Next 10 |
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this Read more ...
NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Liberty Global PLC (NASDAQ:LBTYA), KKR Real Estate Finance Trust Inc....
CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today ann...
Gainers: VivoPower International (NASDAQ: VVPR ) +52% . ENDRA Life Sciences (NASDAQ: NDRA ) +41% . Leap Therapeutics (NASDAQ: LPTX ) +31% . Stitch Fix (NASDAQ: SFIX ) +30% . Seelos Therapeutics (NASDAQ: SEEL ) +26% . Key Energy Services (NYSE: KEG ) +24% . Chaparral Energy (NYS...
Mersana Therapeutics (MRSN) Q4 2018 Earnings Conference Call March 08, 2019 08:00 AM ET Company Participants Sarah Carmody - IR and Corporate Communications Anna Protopapas - CEO Tim Lowinger - Chief Scientific Officer Dave Spellman - CFO Eva Jack - Chief Business Officer ...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Mersana Therapeutics ( MRSN ) Q4 results : Revenues: $1.2M (-63.6%). More news on: Mersana Therapeutics, Healthcare stocks news, Earnings news and commentary, , Read more ...
Mersana Therapeutics (NASDAQ: MRSN ): Q4 GAAP EPS of -$0.97 misses by $0.25 . More news on: Mersana Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Company Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019 Ended 2018 with $70 Million in Cash Further Strengthened Balance Sheet with Gross Proceeds of $98 Million from Equity Financing; Expected to Fund the Company Through Important Clinical Milestones ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...